DexCom (DXCM) Aktienübersicht
DexCom, Inc. ist ein Medizintechnikunternehmen, das sich auf die Konzeption, Entwicklung und Vermarktung von Systemen zur kontinuierlichen Glukoseüberwachung (CGM) für das Management von Diabetes und Stoffwechselerkrankungen in den Vereinigten Staaten und international konzentriert. Mehr Details
| Schneeflocken-Punktzahl | |
|---|---|
| Bewertung | 2/6 |
| Künftiges Wachstum | 2/6 |
| Vergangene Leistung | 6/6 |
| Finanzielle Gesundheit | 6/6 |
| Dividenden | 0/6 |
Belohnungen
Risikoanalyse
DXCM unsere Risikoprüfungen bestanden.
DXCM Community Fair Values
Create NarrativeSee what 145 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
DexCom, Inc. Wettbewerber
Preisentwicklung & Leistung
| Historische Aktienkurse | |
|---|---|
| Aktueller Aktienkurs | US$89.35 |
| 52-Wochen-Hoch | US$92.59 |
| 52-Wochen-Tief | US$54.11 |
| Beta | 1.42 |
| 1 Monat Veränderung | -3.24% |
| 3 Monate Veränderung | 29.36% |
| 1 Jahr Veränderung | 32.47% |
| 3 Jahre Veränderung | 2.11% |
| 5 Jahre Veränderung | -36.26% |
| Veränderung seit IPO | 2,944.29% |
Aktuelle Nachrichten und Updates
Narrative-Update • Sep 03
DXCM: Future CGM Reimbursement Expansion Will Challenge Rich Margin Expectations
DexCom's analyst fair value estimate has been raised from $67.93 to $79.00. This reflects recent Street price target increases that emphasize stronger margins, positive continuous glucose monitoring data, and potential expansion of payer coverage.
Narrative-Update • Aug 15
DXCM: CONNECT Data And Type 2 Access Will Guide Balanced Outlook
DexCom's analyst price target has moved slightly higher to $94.12 from $91.64. This change reflects analysts' updated assumptions after recent Q2 reports, including expectations around continuous glucose monitor adoption, payer coverage opportunities, and margin trends.Recent updates
Narrative-Update • Sep 03
DXCM: Future CGM Reimbursement Expansion Will Challenge Rich Margin Expectations
DexCom's analyst fair value estimate has been raised from $67.93 to $79.00. This reflects recent Street price target increases that emphasize stronger margins, positive continuous glucose monitoring data, and potential expansion of payer coverage.Narrative-Update • Aug 15
DXCM: CONNECT Data And Type 2 Access Will Guide Balanced Outlook
DexCom's analyst price target has moved slightly higher to $94.12 from $91.64. This change reflects analysts' updated assumptions after recent Q2 reports, including expectations around continuous glucose monitor adoption, payer coverage opportunities, and margin trends.Narrative-Update • Jul 31
DXCM: CONNECT Data And Type 2 Expansion Will Shape Balanced Outlook
Analysts have raised their aggregate price target for DexCom to $91.64 from $85.24, citing stronger margin potential, accelerating EPS trends, and support from product rollouts and reimbursement expansion. Analyst Commentary Recent research on DexCom clusters around a generally constructive view on the stock, with most price targets either reaffirmed or adjusted upward and only a few more cautious voices trimming targets.Narrative-Update • Jul 11
DXCM: CONNECT Data In Type 2 Non Insulin Users Will Drive Upside
The analyst price target for DexCom has edged up by about $1.80 to reflect slightly higher fair value estimates and modestly stronger assumptions on future profitability and P/E support, with analysts pointing to fresh Buy initiations, raised targets tied to the CONNECT data in Type 2 non insulin users, and easing concerns around the continuous glucose monitoring market as key drivers of the update. Analyst Commentary Recent research coverage on DexCom reflects a mix of optimism around growth opportunities in Type 2 non insulin users and the broader continuous glucose monitoring market, balanced against more cautious takes on valuation, growth targets, and peer comparisons.Seeking Alpha • Jul 02
DexCom: The Growth Thesis Still Needs To Be Proven
Summary DexCom faces a pivotal transition as GLP-1 adoption threatens its core insulin-treated diabetes market. DXCM aims to expand CGM adoption to Type 2 non-insulin patients, but commercial uptake remains unproven despite positive clinical trial results. At 28x earnings, DXCM's valuation is not demanding, yet offers limited upside given execution risks and the need for evidence of new market penetration. I assign DXCM a Hold rating, pending clearer signs that expansion into non-insulin patients drives sustainable growth. Read the full article on Seeking AlphaNarrative-Update • Jun 26
DXCM: Future CGM Adoption And Trial Data Will Test Premium Expectations
DexCom's analyst fair value estimate has been revised higher to about $67.93. Analysts point to stronger expectations around continuous glucose monitor adoption, positive CONNECT data, and easing concerns following investor day updates as key drivers behind a higher assumed revenue growth rate and a premium future P/E multiple, partly offset by a lower profit margin outlook.Analyseartikel • Jun 20
DexCom (DXCM) Stock Could Be 13.1% Undervalued After Pediatric Stelo Clearance
DexCom (DXCM) is back in focus after US regulators cleared its Stelo Glucose Biosensor System as the first over-the-counter continuous glucose monitor for children who do not use insulin, expanding its reach in the pediatric market. See our latest analysis for DexCom. At a share price of US$72.47, DexCom’s recent 90-day share price return of 8.24% contrasts with a 1-year total shareholder return that declined 9.41%. This suggests recent momentum has picked up after a weaker period, as...Narrative-Update • Jun 09
DXCM: CONNECT Data And Digital Health Expansion Will Shape Balanced Future Outlook
DexCom's analyst price target has moved slightly higher to $83.42 from $81.64, as analysts factor in updated survey work and clinical data that they view as supportive of continuous glucose monitor adoption, particularly in the Type 2 non insulin segment. Analyst Commentary Recent Street research on DexCom reflects a mix of optimism around continuous glucose monitor adoption, especially for Type 2 non insulin users, and more restrained views on valuation and long term targets.Narrative-Update • May 26
DXCM: New Long Term Framework And Buybacks Will Support Future Momentum
Analysts have nudged their average price target for DexCom slightly lower to about $82, reflecting updated assumptions for fair value, discount rate, revenue growth, profit margin and a P/E multiple that are broadly consistent with recent cuts in Street targets to $64 to $82, as firms factor in lower peer multiples and management's new long term guidance. Analyst Commentary Recent research on DexCom clusters around a tighter valuation range, with most firms updating price targets and assumptions after the latest investor and analyst events.Narrative-Update • May 07
DXCM: Share Repurchases And Guidance Reaffirmation Will Support Future Healthcare Momentum
Analysts have trimmed their average price target on DexCom by about $3 to reflect slightly lower modeled revenue growth, a modestly reduced future P/E assumption, and updates to discount rate and margin expectations following a series of recent target changes across Wall Street firms. Analyst Commentary Recent research on DexCom has centered on fine tuning price targets and valuation assumptions rather than making wholesale changes to fundamental views.Neues Narrative • May 02
Type 2 Coverage Expansion And AI Features Will Shape A Balanced Long Term Outlook
Catalysts About DexCom DexCom develops and sells continuous glucose monitoring systems used by people with diabetes around the world. What are the underlying business or industry changes driving this perspective?Narrative-Update • Apr 22
DXCM: AI Coaching And Share Repurchases Will Support Future Healthcare Momentum
Analysts have made a small trim to DexCom's implied value, cutting the analyst price target by about $0.25, as they balance slightly softer modeled growth and margins with generally supportive recent research, including multiple target increases following the latest medtech sector updates. Analyst Commentary Recent research on DexCom reflects a mix of optimism and caution as analysts adjust their models and targets across the medtech group.Narrative-Update • Apr 05
DXCM: AI Coaching And Buybacks Will Support Future Healthcare Momentum
Analysts have nudged DexCom's fair value estimate higher to $87.13 from $86.12, citing a series of upward price target revisions that cluster around the low to mid $80s, while one firm maintains a more cautious view focused on rising competition. Analyst Commentary Recent research on DexCom reflects a split view, with several bullish analysts lifting price targets into the low to mid US$80s, while at least one bearish voice is positioning closer to the low US$70s.Narrative-Update • Mar 22
DXCM: AI Coaching And Buybacks Will Support Future Market Share Confidence
DexCom's fair value estimate edges up by about $0.27 as analysts fine tune assumptions on the discount rate, revenue growth, profit margin, and future P/E, following a mix of price target changes across the Street, including recent upward revisions toward $84 to $86 and a lower $71 target tied to competition concerns. Analyst Commentary Recent Street research on DexCom reflects a split view, with some firms nudging targets higher into the mid $80s and others pushing back toward the low $70s on competition concerns.Narrative-Update • Mar 08
DXCM: AI Coaching And Share Repurchases Will Support Long-Term Confidence
DexCom's intrinsic value estimate nudged higher to $85.85, with analysts modestly lifting price targets, often in the $1 to $12 range, as they weigh recent target increases against a Barclays downgrade that highlights rising competitive pressure in continuous glucose monitoring. Analyst Commentary Recent research on DexCom reflects a split tape, with several firms adjusting price targets higher by amounts in the low single digits to low teens, while one major firm has moved to a more cautious stance with a lower target and an Underweight rating.Narrative-Update • Feb 21
DXCM: Medicare Support And AI Coaching Rollout Will Sustain Long-Term Confidence
Our updated DexCom narrative reflects a small increase in fair value to $85.46. Analysts point to a mix of modestly lower assumed revenue growth, slightly higher profit margin expectations, a reduced future P/E multiple, and a series of recent price target adjustments that are mostly higher in dollar terms despite some concerns around rising competition.Analyseartikel • Feb 19
The Strong Earnings Posted By DexCom (NASDAQ:DXCM) Are A Good Indication Of The Strength Of The Business
Even though DexCom, Inc.'s ( NASDAQ:DXCM ) recent earnings release was robust, the market didn't seem to notice. Our...Narrative-Update • Feb 05
DXCM: Medicare Support And AI Coaching Features Will Sustain Long-Term Confidence
Analysts made only a slight upward tweak to the DexCom price target to about US$85, reflecting small adjustments to their growth, margin and P/E assumptions as they balance caution on rising competition with support from recent positive research updates. Analyst Commentary Recent research on DexCom reflects a split view, with some analysts highlighting supportive policy signals and valuation upside, while others focus on intensifying competition and reduced price targets.Narrative-Update • Jan 22
DXCM: Medicare Support And 2026 Sensor Expansion Will Sustain Long-Term Confidence
Our DexCom price target edges down to about $85 from $85.27, reflecting slightly lower assumed profit margins and P/E multiple, partly offset by analysts citing supportive Medicare reimbursement commentary and mixed Street views on competition, valuation, and 2026 guidance. Analyst Commentary Recent research on DexCom highlights a clear split between bullish and bearish analysts, with views clustering around competition, execution on guidance, and how much investors are willing to pay for the stock through the P/E multiple.Narrative-Update • Jan 07
DXCM: Medicare Support And New Sensor Duration Will Sustain Long-Term Confidence
Analysts nudged their fair value estimate for DexCom slightly higher to about $85 per share, citing a generally supportive regulatory backdrop for continuous glucose monitors and noting that recent price target cuts still reflect confidence in the company’s long term patient growth and product profile. Analyst Commentary Recent research updates on DexCom highlight a mix of optimism around the core continuous glucose monitor franchise and caution around guidance, pricing, and execution into 2026.Narrative-Update • Dec 15
DXCM: Medicare Reimbursement Stability Will Support Confidence Despite Emerging Legal And Safety Headlines
Analysts have nudged our DexCom fair value estimate slightly higher, from $84.31 to $84.85, as they balance recent price target cuts with continued Buy and Outperform ratings that point to resilient growth, stable margins, and a favorable regulatory and product backdrop. Analyst Commentary Street research continues to reflect a constructive long term view on DexCom, even as recent reports incorporate more conservative assumptions and lower base case price targets.Narrative-Update • Nov 29
DXCM: Medicare Payment Developments Will Drive Confidence Despite Recent Short-Term Weakness
DexCom's analyst price target has decreased modestly to approximately $84.31 from $84.96, as analysts cite a mix of positive Medicare policy developments and tempered optimism following company guidance updates and recent survey data. Analyst Commentary Recent analyst research on DexCom reflects both optimism about the company's long-term prospects and concerns regarding near-term execution and growth trends.Narrative-Update • Nov 15
DXCM: Share Recovery Likely With Positive Setup Expected For 2026
Analysts have lowered their price targets for DexCom, reducing the fair value estimate from $98.40 to $84.96. This reflects a reaction to recent conservative guidance, weaker growth outlook, and updated margin expectations.Analyseartikel • Nov 02
Earnings Beat: DexCom, Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models
As you might know, DexCom, Inc. ( NASDAQ:DXCM ) just kicked off its latest quarterly results with some very strong...Narrative-Update • Oct 31
DXCM: Expanding Reimbursement Will Drive Gains Despite Market Uncertainty
The consensus analyst price target for DexCom was recently lowered, with the average fair value estimate moving down by less than $1 to approximately $98.40. Analysts cite investor concerns around the company’s conservative guidance and gross margin pressure, but remain generally positive on long-term growth and patient retention trends.Narrative-Update • Oct 17
Insurance Reimbursement And Digital Health Integration Will Unlock Global Potential
DexCom's average analyst price target has decreased by approximately $1.58 to around $98.96. Analysts are recalibrating their outlook in light of mixed survey results and a shift in assumptions around reimbursement trends and profitability expectations.Narrative-Update • Oct 03
Insurance Reimbursement And Digital Health Integration Will Unlock Global Potential
Analysts have modestly reduced DexCom's fair value estimate by approximately $1.54 to $100.54 per share. This change reflects slightly lower revenue growth projections and recent adjustments in price targets based on mixed survey data and evolving reimbursement trends.Aktionärsrenditen
| DXCM | US Medical Equipment | US Markt | |
|---|---|---|---|
| 7D | 7.6% | 1.6% | -0.2% |
| 1Y | 32.5% | -16.2% | 12.1% |
Rendite im Vergleich zur Industrie: DXCM übertraf die Branche US Medical Equipment , die im vergangenen Jahr eine Rendite von -16.2 erzielte.
Rendite vs. Markt: DXCM übertraf den Markt US, der im vergangenen Jahr eine Rendite von 12.1 erzielte.
Preisvolatilität
| DXCM volatility | |
|---|---|
| DXCM Average Weekly Movement | 6.0% |
| Medical Equipment Industry Average Movement | 8.3% |
| Market Average Movement | 6.8% |
| 10% most volatile stocks in US Market | 15.1% |
| 10% least volatile stocks in US Market | 2.9% |
Stabiler Aktienkurs: DXCM hatte in den letzten 3 Monaten im Vergleich zum US -Markt keine signifikante Preisvolatilität.
Volatilität im Zeitverlauf: DXCMDie wöchentliche Volatilität (6%) ist im vergangenen Jahr stabil geblieben.
Über das Unternehmen
| Gegründet | Mitarbeiter | CEO | Website |
|---|---|---|---|
| 1999 | 11,050 | Jake Leach | www.dexcom.com |
DexCom, Inc. ist ein Medizintechnikunternehmen, das sich auf die Konzeption, Entwicklung und Vermarktung von Systemen zur kontinuierlichen Glukoseüberwachung (CGM) für das Management von Diabetes und Stoffwechselerkrankungen in den Vereinigten Staaten und international konzentriert. Das Unternehmen bietet Dexcom G7 und G7 15 Day, ein integriertes System zur kontinuierlichen Blutzuckermessung, Dexcom G6, ein CGM-System, Dexcom ONE+ als Ersatz für Blutzuckermessungen mit dem Finger bei Entscheidungen zur Diabetesbehandlung, Stelo, einen Biosensor für Erwachsene mit Prädiabetes und Typ-2-Diabetes, die kein Insulin verwenden, Dexcom Share, ein Fernüberwachungssystem, und die Anwendung Dexcom Follow. Das Unternehmen vertreibt seine Produkte direkt an Endokrinologen, Ärzte und Diabetesberater.
DexCom, Inc.'s Grundlagenzusammenfassung
| DXCM grundlegende Statistiken | |
|---|---|
| Marktanteil | US$33.72b |
| Gewinn(TTM) | US$999.70m |
| Umsatz(TTM) | US$4.97b |
33.7x
Kurs-Gewinn-Verhältnis 6.8x
Kurs-Umsatz-VerhältnisIst DXCM zu teuer?
Siehe Fair Value und BewertungsanalyseErträge & Einnahmen
| DXCM Gewinn- und Verlustrechnung (TTM) | |
|---|---|
| Einnahmen | US$4.97b |
| Kosten der Einnahmen | US$1.86b |
| Bruttogewinn | US$3.10b |
| Sonstige Ausgaben | US$2.10b |
| Gewinn | US$999.70m |
Zuletzt gemeldete Gewinne
Jun 30, 2026
Datum des nächsten Gewinnberichts
k.A.
| Gewinn per Aktie (EPS) | 2.65 |
| Bruttomarge | 62.47% |
| Nettogewinnspanne | 20.12% |
| Schulden/Eigenkapital-Verhältnis | 47.4% |
Wie hat sich DXCM auf lange Sicht entwickelt?
Historische Performance und VergleicheUnternehmensanalyse und Finanzdaten Status
| Daten | Zuletzt aktualisiert (UTC-Zeit) |
|---|---|
| Unternehmensanalyse | 2026/09/20 13:37 |
| Aktienkurs zum Tagesende | 2026/09/18 00:00 |
| Gewinne | 2026/06/30 |
| Jährliche Einnahmen | 2025/12/31 |
Datenquellen
Die in unserer Unternehmensanalyse verwendeten Daten stammen von S&P Global Market Intelligence LLC. Die folgenden Daten werden in unserem Analysemodell verwendet, um diesen Bericht zu erstellen. Die Daten sind normalisiert, was zu einer Verzögerung bei der Verfügbarkeit der Quelle führen kann.
| Paket | Daten | Zeitrahmen | Beispiel US-Quelle * |
|---|---|---|---|
| Finanzdaten des Unternehmens | 10 Jahre |
| |
| Konsensschätzungen der Analysten | +3 Jahre |
|
|
| Marktpreise | 30 Jahre |
| |
| Eigentümerschaft | 10 Jahre |
| |
| Verwaltung | 10 Jahre |
| |
| Wichtige Entwicklungen | 10 Jahre |
|
* Beispiel für US-Wertpapiere, für nicht-US-amerikanische Wertpapiere werden gleichwertige regulatorische Formulare und Quellen verwendet.
Sofern nicht anders angegeben, beziehen sich alle Finanzdaten auf einen Jahreszeitraum, werden aber vierteljährlich aktualisiert. Dies wird als Trailing Twelve Month (TTM) oder Last Twelve Month (LTM) Daten bezeichnet. Erfahren Sie mehr.
Analysemodell und Schneeflocke
Details zum Analysemodell, mit dem dieser Bericht erstellt wurde, finden Sie auf unserer Github-Seite; außerdem bieten wir Leitfäden zur Nutzung unserer Berichte und Tutorials auf Youtube an.
Erfahren Sie mehr über das , das das Simply Wall St-Analysemodell entworfen und entwickelt hat.
Metriken für Industrie und Sektor
Unsere Branchen- und Sektionskennzahlen werden alle 6 Stunden von Simply Wall St berechnet. Details zu unserem Verfahren finden Sie auf Github.
Analysten-Quellen
DexCom, Inc. wird von 53 Analysten beobachtet. 27 dieser Analysten hat die Umsatz- oder Gewinnschätzungen übermittelt, die als Grundlage für unseren Bericht dienen. Die von den Analysten übermittelten Daten werden im Laufe des Tages aktualisiert.
| Analyst | Einrichtung |
|---|---|
| Jeffrey Johnson | Baird |
| Matthew Miksic | Barclays |
| Travis Steed | Barclays |